2023
The company is established as a leader in orphan drug therapies.
Who we are
Our Story
The vision of our shareholders, hand in hand with the talent of our team, allows the Stendhal story to continue to be built to meet our motto: Caring for Life.
2023
2021
2021
Stendhal signs licenses with 10 business partners, adding therapies for the care of rare diseases to its portfolio.
2020
2020
The drug Methoxyflurane is included to contribute to the effective and safe treatment of patients with acute, moderate, or severe pain.
2019
2019
Stendhal makes a strategic alliance to expand the distribution and marketing of primary care products in Mexico, Central America, and the Caribbean.
2019
Create independence of access to the microbiology laboratory ID: MB-LAB-04 from the general corridor ID:PO-FB-15, creation of a new warehouse and relocation of raw material storage, relocation of the sampling area and the sample area retention, creation of a transfer for the exit of RPBI waste from the microbiology laboratory ID: MB-LAB-04.Read More
2017
2017
Stendhal’s product portfolio continues to grow with the inclusion of Dimethyl Fumarate, the first oral treatment for multiple sclerosis. Also, incursions into molecules for advanced oncology therapies are initiated.
2015
2015
Stendhal is established across various national rankings as one of the most important companies in Mexico. The company is positioned as one of the Top 500 Mexican Companies.
2013
2013
Commercial agreements are initiated to include innovative molecules for the cardiovascular area in the portfolio. The Cardiovascular Business Unit is formed and a molecule for arterial hypertension is launched. Stendhal becomes the first North American partner of Korea's pharma industry.
2012
2012
Operations begin in the Dominican Republic; Stendhal now operates in 14 countries.
2010
2010
Stendhal is established as an undisputed leader in the treatment of HIV/AIDS and multiple sclerosis, with innovative treatments for critical care and genetic disorders. The product portfolio is strengthened by incorporating the first comprehensive treatment for HIV/AIDS in Mexico in the form of a tablet.
2009
2009
Stendhal partners with Eicopen Pharma, expanding its presence in Central America and the Andean Zone.
2008
2008
Stendhal ventures into Neurology by launching the first monoclonal antibody for the treatment of multiple sclerosis, leading to the creation of the Neurosciences Business Unit.
2007
2007
Stendhal becomes a leader in HIV/AIDS treatments.
2005
2005
Creation of the Oncology Business Unit in a business alliance with Baxter.
2004
2004
Launch of the first line of products for the treatment of HIV/AIDS, which gives rise to the formation of the HIV Business Unit.
2003
2003
Signing of the first commercial agreement with Gilead Sciences Inc. for anti-infective products. The remodeling of the manufacturing site is carried out, achieving high world-class standards in good practices for manufacturing, conditioning and storage, and product distribution and control.
2003
The remodeling of the pharmaceutical plant in the State of Mexico begins. Stendhal's philosophy is developed as a company dedicated to innovative and high-tech medicine for critical conditions that put human life at risk.
1997
1997
A group of Mexican investors acquires Stendhal. A comprehensive transformation occurs by renewing the philosophy and business mission that shaped the company.
1996
1996
Expanding the business vision, Stendhal Plant was acquired, a pharmaceutical laboratory founded in 1974. To give strength to this new organization, measures are implemented to optimize internal processes.
1974
1974
Stendhal is born as a Pharmaceutical Laboratory.
Tel. +(52) 55 2000 66 30
Misdirection: Camino a Santa Teresa No. 1040, Mezzanine Jardines en la Montaña,
Alcaldía Tlalpan, C.P. 14210, Ciudad de México, México
© Stendhal International 2024. All Rights Reserved. Stendhal Pharma is owned by Específicos Stendhal, S.A. de C.V.